Day 181 Generic Drug Launch: The Definitive Analyst’s Guide to Identifying, Timing, and Winning Generic Entry Opportunities
The global generic drugs market was valued at $468.08 billion in 2025 and is projected to reach $728.64 billion by […]
Tips, Tricks, and Case Studies
Maximizing Pharmaceutical Patent Longevity: A Mechanistic and Strategic Guide to IP Term Extension and Lifecycle Fortification
The Economic Imperative of Time In the pharmaceutical sector, time is a tangible asset with a valuation that often exceeds
What Happens When a Drug Patent Expires? Understanding Drug Patent Life
A strategic guide to patent expiry, lifecycle defense, and the economics of generic competition — for executives, investors, and analysts
What Happens When a Drug Patent Expires? Understanding Drug Patent Life Read Post »
Tentative Drug Approvals: The Definitive Generic Entry Forecasting Playbook
Every year, dozens of brand-name drugs approach the end of their patent life with billions in annual revenue at stake.
Tentative Drug Approvals: The Definitive Generic Entry Forecasting Playbook Read Post »
Viagra’s Generic Cliff: Why It Wasn’t a Free-for-All
Executive Summary Pfizer’s management of sildenafil citrate’s loss of exclusivity (LOE) in the United States is the closest thing small-molecule
Viagra’s Generic Cliff: Why It Wasn’t a Free-for-All Read Post »
FDA Unapproved Drugs: The $7.5 Billion 505(b)(2) Opportunity Most Pharma Execs Are Ignoring
The Anomaly That Keeps Paying Here is a fact that surprises most people who work outside drug regulatory affairs: hundreds
Expired Pharma Patents: The $356 Billion Intelligence Asset Most Companies Ignore
How abandoned and expired patents in pharmaceutical manufacturing reveal synthesis routes, competitor strategy, and biosimilar opportunities your R&D team is
Expired Pharma Patents: The $356 Billion Intelligence Asset Most Companies Ignore Read Post »
